Bellerophon Therapeutics Stock Forecast, Price & News

-0.19 (-4.20 %)
(As of 06/17/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume52,381 shs
Average Volume69,798 shs
Market Capitalization$41.16 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive BLPH News and Ratings via Email

Sign-up to receive the latest news and ratings for Bellerophon Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Bellerophon Therapeutics logo

About Bellerophon Therapeutics

Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its products include INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension. The company engages in the development of INOpulse that is in Phase 2 clinical trial for the treatment of pulmonary hypertension associated with fibrotic interstitial lung disease; that has completed Phase 2a clinical trial for pulmonary hypertension associated with chronic obstructive pulmonary disease; and that is in Phase 2 dose escalation stage for pulmonary hypertension associated with sarcoidosis, as well as for chronic thromboembolic pulmonary hypertension, pulmonary hypertension associated with pulmonary edema from high altitude sickness, and COVID-19 patients. The company was formerly known as Ikaria Development LLC and changed its name to Bellerophon Therapeutics, Inc. in January 2014. Bellerophon Therapeutics, Inc. was founded in 2009 and is headquartered in Warren, New Jersey.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.41 out of 5 stars

Medical Sector

726th out of 2,100 stocks

Pharmaceutical Preparations Industry

358th out of 831 stocks

Analyst Opinion: 3.5Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Bellerophon Therapeutics (NASDAQ:BLPH) Frequently Asked Questions

Is Bellerophon Therapeutics a buy right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Bellerophon Therapeutics in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Bellerophon Therapeutics stock.
View analyst ratings for Bellerophon Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Bellerophon Therapeutics?

Wall Street analysts have given Bellerophon Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Bellerophon Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Bellerophon Therapeutics' next earnings date?

Bellerophon Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, August 4th 2021.
View our earnings forecast for Bellerophon Therapeutics

How were Bellerophon Therapeutics' earnings last quarter?

Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) announced its earnings results on Monday, May, 10th. The biotechnology company reported ($0.58) earnings per share for the quarter, topping analysts' consensus estimates of ($0.71) by $0.13.
View Bellerophon Therapeutics' earnings history

How has Bellerophon Therapeutics' stock price been impacted by Coronavirus (COVID-19)?

Bellerophon Therapeutics' stock was trading at $6.29 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, BLPH shares have decreased by 31.2% and is now trading at $4.33.
View which stocks have been most impacted by COVID-19

When did Bellerophon Therapeutics' stock split? How did Bellerophon Therapeutics' stock split work?

Bellerophon Therapeutics shares reverse split before market open on Monday, February 10th 2020. The 1-15 reverse split was announced on Friday, February 7th 2020. The number of shares owned by shareholders was adjusted after the market closes on Friday, February 7th 2020. An investor that had 100 shares of Bellerophon Therapeutics stock prior to the reverse split would have 7 shares after the split.

What price target have analysts set for BLPH?

3 analysts have issued 1-year price objectives for Bellerophon Therapeutics' shares. Their forecasts range from $19.00 to $30.00. On average, they anticipate Bellerophon Therapeutics' stock price to reach $23.67 in the next twelve months. This suggests a possible upside of 446.6% from the stock's current price.
View analysts' price targets for Bellerophon Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Bellerophon Therapeutics' key executives?

Bellerophon Therapeutics' management team includes the following people:
  • Mr. Fabian Tenenbaum, CEO & Director (Age 47, Pay $825.73k)
  • Mr. Assaf Korner, CFO & Sec. (Age 43, Pay $406.48k)
  • Mr. Peter Fernandes, Chief Regulatory & Safety Officer (Age 66, Pay $476.35k)
  • Dr. Parag Suresh Shah, VP of Bus. Operations (Age 44)
  • Ms. Amy Edmonds, VP of Clinical Operations & Admin. (Age 49)
  • Dr. Edwin L. Parsley, Acting Chief Medical Officer (Age 60)

Who are some of Bellerophon Therapeutics' key competitors?

What other stocks do shareholders of Bellerophon Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Bellerophon Therapeutics investors own include Inovio Pharmaceuticals (INO), Vaxart (VXRT), Corbus Pharmaceuticals (CRBP), Novavax (NVAX), Pfizer (PFE), Verastem (VSTM), Gilead Sciences (GILD), OPKO Health (OPK), SCYNEXIS (SCYX) and Dynavax Technologies (DVAX).

When did Bellerophon Therapeutics IPO?

(BLPH) raised $60 million in an initial public offering on Friday, February 13th 2015. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. Leerink Partners and Cowen and Company acted as the underwriters for the IPO and FBR and SunTrust Robinson Humphrey were co-managers.

What is Bellerophon Therapeutics' stock symbol?

Bellerophon Therapeutics trades on the NASDAQ under the ticker symbol "BLPH."

Who are Bellerophon Therapeutics' major shareholders?

Bellerophon Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (3.39%), New Mountain Vantage Advisers L.L.C. (2.66%), Renaissance Technologies LLC (2.46%), DAVENPORT & Co LLC (1.04%), Caas Capital Management LP (1.03%) and Northern Trust Corp (0.80%). Company insiders that own Bellerophon Therapeutics stock include Associates Iv L P Venrock, New Mountain Investments Ii, L, Theodore T Wang and Wassim Fares.
View institutional ownership trends for Bellerophon Therapeutics

Which institutional investors are selling Bellerophon Therapeutics stock?

BLPH stock was sold by a variety of institutional investors in the last quarter, including New Mountain Vantage Advisers L.L.C., and Northern Trust Corp.
View insider buying and selling activity for Bellerophon Therapeutics
or view top insider-selling stocks.

Which institutional investors are buying Bellerophon Therapeutics stock?

BLPH stock was acquired by a variety of institutional investors in the last quarter, including Caas Capital Management LP, Citadel Advisors LLC, Tudor Investment Corp Et Al, Citadel Advisors LLC, Laurion Capital Management LP, Renaissance Technologies LLC, Squarepoint Ops LLC, and Element Capital Management LLC. Company insiders that have bought Bellerophon Therapeutics stock in the last two years include Theodore T Wang, and Wassim Fares.
View insider buying and selling activity for Bellerophon Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Bellerophon Therapeutics?

Shares of BLPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Bellerophon Therapeutics' stock price today?

One share of BLPH stock can currently be purchased for approximately $4.33.

How much money does Bellerophon Therapeutics make?

Bellerophon Therapeutics has a market capitalization of $41.16 million. The biotechnology company earns $-24,730,000.00 in net income (profit) each year or ($3.06) on an earnings per share basis.

How many employees does Bellerophon Therapeutics have?

Bellerophon Therapeutics employs 21 workers across the globe.

What is Bellerophon Therapeutics' official website?

The official website for Bellerophon Therapeutics is

Where are Bellerophon Therapeutics' headquarters?

Bellerophon Therapeutics is headquartered at 184 LIBERTY CORNER ROAD SUITE 302, WARREN NJ, 07059.

How can I contact Bellerophon Therapeutics?

Bellerophon Therapeutics' mailing address is 184 LIBERTY CORNER ROAD SUITE 302, WARREN NJ, 07059. The biotechnology company can be reached via phone at 908-574-4770 or via email at [email protected]

This page was last updated on 6/18/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.